NBIX stock forecast, quote, news & analysis
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders... Show more
Why Neurocrine Biosciences (NBIX) Stock Is Down -13.9% in the Last 30 Days
Key Takeaways
- Neurocrine Biosciences (NBIX) shares declined roughly 13.9% over the trailing 30-day period, falling from about $157.22 to near $135 in mid-October 2026.
- The pullback was compounded by a BMO Capital price-target cut to $150 from $164, which cited Ingrezza pricing headwinds and a regulatory overhang.
- Broader pressure on small- and mid-cap biotech from rising interest rates also weighed on the stock, despite broadly positive sell-side ratings.
- Fundamentals remained strong in the most recent quarter, with revenue up about 39.5% year over year, led by record Ingrezza sales.
- A Chief Medical Officer transition and notable insider selling added to near-term investor caution.
Neurocrine Biosciences (NBIX) Company Overview and Market Position
Neurocrine Biosciences, Inc. is a San Diego–based neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Its commercial portfolio is anchored by INGREZZA (valbenazine), a first-in-class VMAT2 inhibitor approved for tardive dyskinesia and for chorea associated with Huntington's disease. INGREZZA remains the company's flagship product and has generated more than $700 million in quarterly net sales.
The company has diversified beyond a single product. CRENESSITY (crinecerfont), approved for congenital adrenal hyperplasia, has scaled rapidly since its launch, and VYKAT XR (diazoxide choline), used to treat hyperphagia in Prader-Willi syndrome, was added through the acquisition of Soleno Therapeutics completed in May 2026. Neurocrine also holds a women's health collaboration with AbbVie (ABBV) covering ORILISSA and ORIAHNN. Investors follow NBIX for its growing commercial portfolio, late-stage neuroscience pipeline, and consistent cash-flow generation.
Neurocrine Biosciences (NBIX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NBIX fell from a closing price near $157.22 in mid-September to about $135 in mid-October 2026, a decline of approximately 13.9%. The move pushed shares below both their 50-day and 200-day moving averages and well under their 52-week high of $186.12, while remaining above the 52-week low of $122.14.
The three-month trend has been more pronounced. From a level near $172 in mid-July, the stock has shed roughly 21% through mid-October, reflecting a sustained period of multiple compression and investor de-risking in the biopharma sector rather than a single isolated event. The decline has occurred even as the company continued to report accelerating revenue growth, underscoring the gap between operating performance and market sentiment.
What Drove NBIX Stock Price in the Last 30 Days
Several verified factors contributed to the 30-day decline. In early October, BMO Capital lowered its price target on Neurocrine to $150 from $164 while maintaining a Market Perform rating, citing Ingrezza pricing headwinds and a regulatory overhang related to the VYKAT XR franchise. The note also pointed to rising interest rates as a headwind for small- and mid-cap biotech valuations.
The stock also absorbed a leadership change, as the company announced the return of Dr. Eiry Roberts as Chief Medical Officer effective September 28, 2026, replacing Dr. Sanjay Keswani, who departed by mutual agreement. While framed as a move toward continuity, the transition added near-term execution uncertainty. Persistent insider selling, reported at roughly $77.9 million over the trailing year with limited buying activity, further dampened sentiment even as several analysts reiterated constructive views, including Buy ratings and elevated price targets from Citi, RBC Capital, and Jefferies.
What Drove NBIX Stock Performance Over the Last Quarter
The broader three-month decline reflects a shift in market tone rather than a deterioration in fundamentals. During the quarter, the company reported strong second-quarter results, with revenue of approximately $959 million, up 39.5% year over year, and non-GAAP EPS of $2.85, well above consensus. Ingrezza generated record quarterly net sales of about $716 million, up 15%, while CRENESSITY contributed roughly $184 million.
Despite these results, the shares compressed as investors weighed pricing and rebate pressures, integration costs tied to the Soleno acquisition, and a broader rotation away from high-multiple biotech names amid higher interest rates. The result has been a valuation reset: NBIX now trades at a trailing P/E near 20, well below its historical five-year median, even as the consensus analyst rating remains broadly positive.
Trending AI Robots
For traders seeking a data-driven, systematic approach to stocks like NBIX, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this curated section. Each bot operates with its own strategy, timeframe, and performance metrics, giving users a way to compare approaches and monitor results in real time. Exploring the section can help investors identify automated strategies that align with their own objectives and risk tolerance.
NBIX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most immediate catalyst is Neurocrine's third-quarter earnings report, scheduled for early November 2026. Investors will focus on Ingrezza prescription trends and net pricing, CRENESSITY launch momentum, and VYKAT XR integration progress following the Soleno acquisition, as well as any updates to full-year guidance.
Beyond earnings, key watch items include regulatory clarity around the VYKAT XR franchise, payer and rebate dynamics for Ingrezza, and clinical readouts from the late-stage pipeline, including programs in major depressive disorder and schizophrenia expected to advance toward 2027 milestones. Macroeconomic conditions, particularly the path of interest rates, and ongoing insider selling activity will also remain important sentiment indicators. These factors should be evaluated alongside the company's underlying revenue growth rather than in isolation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NBIX in upward trend: price rose above 50-day moving average on November 03, 2026
NBIX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NBIX as a result. In 62 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +2.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 224 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
NBIX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBIX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.531) is normal, around the industry mean (6.379). P/E Ratio (23.352) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a product based biopharmaceutical company
Industry PharmaceuticalsGeneric